Systemic and topical steroids in the management of oral mucosal lesions

Kiran, M Shashi; Vidya, Sree; Aswal, Gunjan Singh; Kumar, Vinod; Rai, Vineet

doi:10.4103/jpbs.jpbs_91_17

Cited by 18 publications

(17 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Topical and/or systemic corticosteroids with or without immunosuppressive drugs, Dapsone, and Tetracycline are among the widely alternative treatment regimens. 34 Among the topical medications, studies have reported good results in patients with oral lesions. However, it can be difficult to apply and maintain corticosteroids in extensive and deep gingival lesions.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Oral Lesions in Dermatological Diseases: A Retrospective Study

Teixeira‐Souza

Pessôa

Ramos

et al. 2020

Rev. Bras. Odontol.

View full text Add to dashboard Cite

Objetivo: Este estudo teve como objetivo estabelecer a prevalência das lesões orais nas doenças dermatológicas. Material e Métodos: A população do estudo consistiu de 119 pacientes com dermatoses (conforme prontuário). Os dados demográficos e clínicos coletados incluem sexo, cor da pele, idade do diagnóstico e localização anatômica de lesão. Resultados: Prevalência significativa do sexo feminino (n = 74; 63%; p = 0,01) e cor de pele branca (n=7; 65%; p<0,001). A idade do diagnóstico variou de 10 a 86 anos, com alta prevalência de indivíduos >20 anos (n= 6; 73%; p=0,05). A lesão mais frequente foi o pênfigo vulgar (38%), seguido de líquen plano oral (30%); Penfigóide (17%); Lúpus Eritematoso (10%); Eritema multiforme e Epidermólise bolhosa (3%); Estomatite Ulcerativa Crônica e Pioestomatite vegetante (1%). Conclusão: As doenças dermatológicas podem afetar a mucosa oral, causando impacto significativo na qualidade de vida dos pacientes, o que compreendeu principalmente a população jovem em nosso estudo. O pênfigo vulgar foi a doença mais prevalente. O monitoramento contínuo por uma equipe multidisciplinar é essencial, uma vez que esse grupo de doenças não tem cura e/ou prognóstico variável.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of Oral Lesions in Dermatological Diseases: A Retrospective Study

Teixeira‐Souza

Pessôa

Ramos

et al. 2020

Rev. Bras. Odontol.

View full text Add to dashboard Cite

show abstract

“…Microarray analysis studies have shown that dexpanthenol improves wound healing by increasing the IL-6 and IL-8 expression. 17 3) Topical Analgesic Agents and Mouthwashes a) Mouthwashes The goal of the antimicrobial mouthwashes frequently used in dental clinical practice is to reduce the number of microorganisms in the oral cavity. Chlorhexidine gluconate and benzydamine hydrochloride are the most commonly used active ingredients in antimicrobial mouthwashes.…”

Section: Hydrocortisone Acetatementioning

confidence: 99%

Drugs used in the treatment of oral mucosal diseases

Karapinar¹,

Ünür²

2019

Yeditepe J Dent

View full text Add to dashboard Cite

The oral mucosa and the surrounding tissues are the entrance to the body, where oral mucosa-specific lesions can be seen, and where symptoms or signs of many systemic diseases can be observed. The etiology of the lesions occurring in the oral mucosa may be trauma, infection, immunological causes or idiopathic. Drug application onto the mucosa covering the oral cavity has long been a field of pharmacology. Lesions that occur as a symptom of systemic diseases are usually seen as ulcerations. The purpose of the treatment is to apply symptomatic treatments that mainly improve the patient's comfort while solving the underlying problem. These are achieved primarily by correcting oral hygiene, regulating the diet, and prescribing medicines in the appropriate manner mentioned in the article. In this review, we aimed to review the drugs used in oral mucosal diseases by the dentists who frequently deal with them.

show abstract

“…The current standard treatment of VBD is based on systemic oral corticosteroids (CS) or on systemic steroid‐sparing agents 3 . Even though oral VBD respond well to systemic steroids, adverse side effects sometimes limit their use 4 and lead to the increased use of topical CS 5 …”

Section: Introductionmentioning

confidence: 99%

“…Topical CS and intra‐lesional steroid injections are the main treatments for isolated oral VBD lesions (such as in MMP) or persistent oral lesions (such as in PV) with or without systemic medications. In these cases, application of potent steroids such as clobetasol propionate 0.05% is beneficial, as well as dexamethasone 0.5 mg/5 mL oral rinse, or triamcinolone acetonide 0.1%‐0.5% in the form of an aqueous rinse or ointment 3 …”

Section: Introductionmentioning

confidence: 99%

“…In these cases, application of potent steroids such as clobetasol propionate 0.05% is beneficial, as well as dexamethasone 0.5 mg/5 mL oral rinse, or triamcinolone acetonide 0.1%-0.5% in the form of an aqueous rinse or ointment. 3 Here, we describe our clinical experience in treating DG patients with potent CS applied in custom-made silicone trays, a unique and safe method of targeted topical application that locally suppresses clinical signs and symptoms and limits the area of contact of medications to the involved gingival surface. This method prevents unnecessary absorption through any healthy mucosal surfaces, and thus, has the potential to reduce the local and systemic side effects.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Custom‐made trays for targeted treatment of oral vesiculobullous diseases: A proposed protocol

Amy

Kassem

2020

Dermatologic Therapy

View full text Add to dashboard Cite

Topical and intralesional corticosteroids (CS) are effective treatments for oral manifestations of autoimmune vesiculobullous diseases (VBD); however, may cause unnecessary absorption in the adjacent healthy mucosal surfaces, local infections, atrophy, and injection pain. To propose a protocol using a unique modality for targeted administration of CS for the treatment of local manifestations of oral VBD. The medical records of nine patients with systemic CS-resistant VBD oral lesions, were reviewed following 3 weeks of treatment and 3 months of tapering using a custom-made tray designed for precise application of topical CS targeted to the involved mucosa. Following treatment, lesions have healed in 8/9 patients. Involvement of surrounding mucosa was minimal, and no systemic adverse effects were recorded. The proposed protocol using custom-made trays for targeted CS treatment could be an effective alternative treatment for oral VBD.

show abstract

Systemic and topical steroids in the management of oral mucosal lesions

Cited by 18 publications

References 17 publications

Prevalence of Oral Lesions in Dermatological Diseases: A Retrospective Study

Prevalence of Oral Lesions in Dermatological Diseases: A Retrospective Study

Drugs used in the treatment of oral mucosal diseases

Custom‐made trays for targeted treatment of oral vesiculobullous diseases: A proposed protocol

Contact Info

Product

Resources

About